DE-QPS-HOLDINGS
26.6.2024 21:00:28 CEST | Business Wire | Press release
QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy facility, and enhanced PBMC capabilities will complement existing bioanalysis, translational medicine and peripheral blood mononuclear cell (PMBC) laboratories and extend the current QPS full-service global CRO offerings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626261072/en/
QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials and houses central lab, safety lab, PBMC and cell production services in Springfield, Missouri. (Photo: Business Wire)
QPS now offers clinical trial sample analysis services and leukopak cell therapy products from its newly expanded clinical trials unit conveniently located in Springfield, Missouri. In addition, QPS has also expanded PBMC service offerings from its Miami, Florida location into its Springfield, Missouri laboratories. The new facilities are housed with an existing clinical (safety) laboratory, a modern self-contained pharmacy, and dedicated space to build and ship clinical trial kits.
The modern central laboratory for sample analysis complements the existing on-site safety laboratory, equipped with the most up-to-date technologies for chemistry, urinalysis, serology, coagulation, and hematology testing. These capabilities, designed to monitor subject safety during ongoing clinical trials, will remain as core services for QPS in-house clinical trials.
The new leukopak products collection and processing facility is designed to meet the exponential growing demand for blood products to support cell therapy research and QPS is ideally placed to provide this service. QPS Missouri has a database of over 35,000 potential study participants, who can be contacted as potential blood donors for leukopak products.
“There is significant unmet demand in this rapidly growing area of cell therapy products, which represents a tremendous opportunity for QPS. Over 3,000 cell and gene therapy programs are currently in progress representing a 20% increase over the past five years. These programs require leukopak products to move forward, and as a result this market is forecasted to grow by a CAGR of more than 8% over the next six years,” said Benjamin Chien, Chairman, President and CEO of QPS.
The enhanced PBMC services include a new PBMC processing lab at the Springfield location, complementing the existing lab at QPS Miami in Miami, Florida. This new lab will support a current unmet need for PBMC processing in the midwestern USA. PBMC sample analysis is a time-consuming process, typically required in vaccine trials, and it is best done in a lab adjacent to the clinical trial unit. QPS is uniquely positioned to offer this service.
“These new facilities, services and products extend our full service CRO capabilities, putting QPS in a position to offer clients comprehensive clinical research services in one location. The central lab, PBMC lab, and the leukopack facility complement and enhance our current 240 bed clinical trials unit, safety laboratory, modern self-contained pharmacy, and clinical trial kit production facility,” said Brendon Bourg, Vice President, Early Phase Clinical and Head of Administration at QPS Missouri.
ABOUT QPS HOLDINGS, LLC
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626261072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom